Researchers on Friday presented detailed investigations into a gene therapy death that last year sparked fear and uncertainty among scientists who believed they had approached powerful treatments for a long list of brain diseases.
The researchers did not conclude precisely what led to the patient’s death, but proposed experiments to test future treatments.
“What I want everyone to take away is: I think we’re starting to build a framework to test this,” said Nicholas Flytzanis, director of research and innovation at Capsida Biotherapeutics. “I think it can be tested, and I think this new specific risk is one that we can try to mitigate and predict in the future.”

This article is reserved for STAT+ subscribers
Unlock this article – plus daily coverage and analysis of the biotech sector – by subscribing to STAT+.
Already have an account? Log in
See all packages
Gn Health
